TWI492937B - 噻萘普汀硫酸鹽型式及其製造及使用的方法 - Google Patents

噻萘普汀硫酸鹽型式及其製造及使用的方法 Download PDF

Info

Publication number: TWI492937B
Authority: TW; Taiwan
Prior art keywords: tianeptine; monohydrate; hemisulfate; methyldibenzo; chloro
Prior art date: 2008-10-31

Application number

TW098136937A

Other languages

English (en)

Chinese (zh)

Other versions

TW201029981A (en

Inventor

Hector Guzman

Alexey Popov

Thomas Joachim Landewald Rammeloo

Julius Remenar

Jihad B Saoud

Mark Tawa

Original Assignee

Transform Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-31

Filing date

2009-10-30

Publication date

2015-07-21

2009-10-30 Application filed by Transform Pharmaceuticals Inc filed Critical Transform Pharmaceuticals Inc

2010-08-16 Publication of TW201029981A publication Critical patent/TW201029981A/zh

2015-07-21 Application granted granted Critical

2015-07-21 Publication of TWI492937B publication Critical patent/TWI492937B/zh

Links

238000000034 method Methods 0.000 title claims description 72
229960005138 tianeptine Drugs 0.000 title description 402
JICJBGPOMZQUBB-UHFFFAOYSA-N 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 JICJBGPOMZQUBB-UHFFFAOYSA-N 0.000 claims description 344
-1 3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepine-11-yl Chemical group 0.000 claims description 99
239000008194 pharmaceutical composition Substances 0.000 claims description 80
239000000203 mixture Substances 0.000 claims description 71
238000000634 powder X-ray diffraction Methods 0.000 claims description 70
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 58
238000013270 controlled release Methods 0.000 claims description 57
241000124008 Mammalia Species 0.000 claims description 47
239000003826 tablet Substances 0.000 claims description 40
239000003814 drug Substances 0.000 claims description 39
239000002904 solvent Substances 0.000 claims description 34
VCSZKSHWUBFOOE-UHFFFAOYSA-N dioxidanium;sulfate Chemical compound O.O.OS(O)(=O)=O VCSZKSHWUBFOOE-UHFFFAOYSA-N 0.000 claims description 32
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 30
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 30
239000007937 lozenge Substances 0.000 claims description 28
238000004458 analytical method Methods 0.000 claims description 26
230000036470 plasma concentration Effects 0.000 claims description 25
150000001875 compounds Chemical class 0.000 claims description 20
159000000000 sodium salts Chemical class 0.000 claims description 20
239000013078 crystal Substances 0.000 claims description 18
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 14
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 14
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 14
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 14
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
238000001179 sorption measurement Methods 0.000 claims description 13
150000001412 amines Chemical class 0.000 claims description 10
229920000642 polymer Polymers 0.000 claims description 10
239000011541 reaction mixture Substances 0.000 claims description 5
HLKOWEUTUIOPFA-UHFFFAOYSA-N 3-chloro-6-methyl-11H-benzo[c][2,1]benzothiazepine Chemical compound ClC1=CC2=C(CC3=C(N(S2)C)C=CC=C3)C=C1 HLKOWEUTUIOPFA-UHFFFAOYSA-N 0.000 claims description 4
ZTHVLZXTYSAELD-UHFFFAOYSA-N 7-[(3-chloro-6-methyl-11h-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid Chemical compound CN1SC2=CC(Cl)=CC=C2C(NCCCCCCC(O)=O)C2=CC=CC=C12 ZTHVLZXTYSAELD-UHFFFAOYSA-N 0.000 claims description 4
239000012530 fluid Substances 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
238000001035 drying Methods 0.000 claims description 3
230000002496 gastric effect Effects 0.000 claims description 3
238000000338 in vitro Methods 0.000 claims description 3
238000005406 washing Methods 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
230000007704 transition Effects 0.000 claims description 2
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims 40
230000015572 biosynthetic process Effects 0.000 claims 1
239000013067 intermediate product Substances 0.000 claims 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 103
229910019142 PO4 Inorganic materials 0.000 description 97
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 97
239000010452 phosphate Substances 0.000 description 97
VALUNVMGXVWSGM-UHFFFAOYSA-N 7-[(3-chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid hydrochloride Chemical compound Cl.O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 VALUNVMGXVWSGM-UHFFFAOYSA-N 0.000 description 79
KVVMXNNJBVTOSX-UHFFFAOYSA-N 7-[(3-chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid sulfuric acid dihydrate Chemical compound O.O.OS(O)(=O)=O.O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21.O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 KVVMXNNJBVTOSX-UHFFFAOYSA-N 0.000 description 43
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
239000000243 solution Substances 0.000 description 36
238000009472 formulation Methods 0.000 description 35
229940079593 drug Drugs 0.000 description 33
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 29
239000002552 dosage form Substances 0.000 description 29
150000004682 monohydrates Chemical class 0.000 description 29
238000011282 treatment Methods 0.000 description 27
238000012360 testing method Methods 0.000 description 26
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
241001465754 Metazoa Species 0.000 description 25
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
239000008186 active pharmaceutical agent Substances 0.000 description 18
230000000694 effects Effects 0.000 description 18
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
238000002411 thermogravimetry Methods 0.000 description 17
239000012453 solvate Substances 0.000 description 16
239000012458 free base Substances 0.000 description 15
150000002500 ions Chemical class 0.000 description 15
238000004090 dissolution Methods 0.000 description 12
239000012729 immediate-release (IR) formulation Substances 0.000 description 12
239000007787 solid Substances 0.000 description 12
239000000725 suspension Substances 0.000 description 12
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 12
239000003981 vehicle Substances 0.000 description 12
238000002425 crystallisation Methods 0.000 description 11
230000008025 crystallization Effects 0.000 description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 10
241000699670 Mus sp. Species 0.000 description 10
238000010521 absorption reaction Methods 0.000 description 10
230000003204 osmotic effect Effects 0.000 description 10
239000011734 sodium Substances 0.000 description 10
229910052708 sodium Inorganic materials 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 8
239000011521 glass Substances 0.000 description 8
239000000546 pharmaceutical excipient Substances 0.000 description 8
239000002504 physiological saline solution Substances 0.000 description 8
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 7
208000006673 asthma Diseases 0.000 description 7
238000001938 differential scanning calorimetry curve Methods 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
238000005259 measurement Methods 0.000 description 7
239000006186 oral dosage form Substances 0.000 description 7
238000005303 weighing Methods 0.000 description 7
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 6
239000000935 antidepressant agent Substances 0.000 description 6
208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 6
230000008901 benefit Effects 0.000 description 6
239000002775 capsule Substances 0.000 description 6
150000001768 cations Chemical class 0.000 description 6
239000007789 gas Substances 0.000 description 6
150000004677 hydrates Chemical class 0.000 description 6
230000009467 reduction Effects 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
238000012546 transfer Methods 0.000 description 6
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 5
229940005513 antidepressants Drugs 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
230000003111 delayed effect Effects 0.000 description 5
238000013461 design Methods 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
150000001450 anions Chemical class 0.000 description 4
230000003542 behavioural effect Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000000460 chlorine Substances 0.000 description 4
229910052801 chlorine Inorganic materials 0.000 description 4
230000008030 elimination Effects 0.000 description 4
238000003379 elimination reaction Methods 0.000 description 4
230000006872 improvement Effects 0.000 description 4
239000006210 lotion Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 4
239000008203 oral pharmaceutical composition Substances 0.000 description 4
FWFGVMYFCODZRD-UHFFFAOYSA-N oxidanium;hydrogen sulfate Chemical compound O.OS(O)(=O)=O FWFGVMYFCODZRD-UHFFFAOYSA-N 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000010926 purge Methods 0.000 description 4
238000011160 research Methods 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
230000009182 swimming Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
238000001757 thermogravimetry curve Methods 0.000 description 4
208000020401 Depressive disease Diseases 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
229920003091 Methocel™ Polymers 0.000 description 3
PKCGGIXXMMAGJZ-UHFFFAOYSA-N O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O Chemical compound O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O PKCGGIXXMMAGJZ-UHFFFAOYSA-N 0.000 description 3
238000001069 Raman spectroscopy Methods 0.000 description 3
238000001237 Raman spectrum Methods 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
238000000862 absorption spectrum Methods 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
229910052782 aluminium Inorganic materials 0.000 description 3
230000001430 anti-depressive effect Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000000576 coating method Methods 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
238000007405 data analysis Methods 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
229910021641 deionized water Inorganic materials 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
238000001914 filtration Methods 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
239000000499 gel Substances 0.000 description 3
208000002551 irritable bowel syndrome Diseases 0.000 description 3
239000008297 liquid dosage form Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
239000004570 mortar (masonry) Substances 0.000 description 3
239000002674 ointment Substances 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
229940127557 pharmaceutical product Drugs 0.000 description 3
238000012545 processing Methods 0.000 description 3
238000005070 sampling Methods 0.000 description 3
ZLBSUOGMZDXYKE-UHFFFAOYSA-M sodium;7-[(3-chloro-6-methyl-5,5-dioxo-11h-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoate Chemical compound [Na+].O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC([O-])=O)C2=CC=C(Cl)C=C21 ZLBSUOGMZDXYKE-UHFFFAOYSA-M 0.000 description 3
239000007909 solid dosage form Substances 0.000 description 3
239000008247 solid mixture Substances 0.000 description 3
238000000527 sonication Methods 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
229910021653 sulphate ion Inorganic materials 0.000 description 3
239000000829 suppository Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
239000007916 tablet composition Substances 0.000 description 3
239000006208 topical dosage form Substances 0.000 description 3
238000002211 ultraviolet spectrum Methods 0.000 description 3
0 CCCNNC#*C Chemical compound CCCNNC#*C 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
206010017999 Gastrointestinal pain Diseases 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
238000004847 absorption spectroscopy Methods 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
239000010949 copper Substances 0.000 description 2
239000006071 cream Substances 0.000 description 2
238000002788 crimping Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000012738 dissolution medium Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000007902 hard capsule Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000012728 immediate-release (IR) tablet Substances 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000013563 matrix tablet Substances 0.000 description 2
238000002483 medication Methods 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
229940126701 oral medication Drugs 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229960005489 paracetamol Drugs 0.000 description 2
230000002688 persistence Effects 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
230000035479 physiological effects, processes and functions Effects 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
239000010453 quartz Substances 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
239000007905 soft elastic gelatin capsule Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
238000000870 ultraviolet spectroscopy Methods 0.000 description 2
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
206010000117 Abnormal behaviour Diseases 0.000 description 1
206010006582 Bundle branch block right Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000008081 Intestinal Fistula Diseases 0.000 description 1
229920004011 Macrolon® Polymers 0.000 description 1
229920003094 Methocel™ K4M Polymers 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
238000011785 NMRI mouse Methods 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
229920001131 Pulp (paper) Polymers 0.000 description 1
239000005864 Sulphur Substances 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
XOCUXOWLYLLJLV-UHFFFAOYSA-N [O].[S] Chemical compound [O].[S] XOCUXOWLYLLJLV-UHFFFAOYSA-N 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000012491 analyte Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000002585 base Substances 0.000 description 1
238000010009 beating Methods 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
238000005266 casting Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
238000005056 compaction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000007872 degassing Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
238000000113 differential scanning calorimetry Methods 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
239000003596 drug target Substances 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
238000007580 dry-mixing Methods 0.000 description 1
229940095107 e.s.p. Drugs 0.000 description 1
239000004495 emulsifiable concentrate Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
235000020650 eye health related herbal supplements Nutrition 0.000 description 1
235000020937 fasting conditions Nutrition 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
239000010439 graphite Substances 0.000 description 1
229910002804 graphite Inorganic materials 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000005286 illumination Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
238000009740 moulding (composite fabrication) Methods 0.000 description 1
239000000820 nonprescription drug Substances 0.000 description 1
238000010606 normalization Methods 0.000 description 1
230000010355 oscillation Effects 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
TWHXWYVOWJCXSI-UHFFFAOYSA-N phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O TWHXWYVOWJCXSI-UHFFFAOYSA-N 0.000 description 1
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000005086 pumping Methods 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
238000010079 rubber tapping Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
238000004467 single crystal X-ray diffraction Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
239000006211 transdermal dosage form Substances 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
238000002562 urinalysis Methods 0.000 description 1
238000012795 verification Methods 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000019195 vitamin supplement Nutrition 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

TW098136937A 2008-10-31 2009-10-30 噻萘普汀硫酸鹽型式及其製造及使用的方法 TWI492937B (zh)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US11000908P	2008-10-31	2008-10-31
US11000108P	2008-10-31	2008-10-31
US11000608P	2008-10-31	2008-10-31
US22834309P	2009-07-24	2009-07-24

Publications (2)

Publication Number	Publication Date
TW201029981A TW201029981A (en)	2010-08-16
TWI492937B true TWI492937B (zh)	2015-07-21

Family

ID=43447880

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW098136937A TWI492937B (zh)	2008-10-31	2009-10-30	噻萘普汀硫酸鹽型式及其製造及使用的方法

Country Status (4)

Country	Link
AR (1)	AR075295A1 (ar)
JO (1)	JO2844B1 (ar)
TW (1)	TWI492937B (ar)
UY (1)	UY32216A (ar)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3758528A (en) *	1970-03-13	1973-09-11	Science Union & Cie	Tricyclic compounds
US6599896B1 (en) *	1999-04-07	2003-07-29	Les Laboratoires Servier	Use of tianeptine in the production of medicaments to treat neurodegenerative pathologies

2009
- 2009-10-29 JO JO2009398A patent/JO2844B1/ar active
- 2009-10-30 AR ARP090104204 patent/AR075295A1/es unknown
- 2009-10-30 TW TW098136937A patent/TWI492937B/zh not_active IP Right Cessation
- 2009-10-30 UY UY32216A patent/UY32216A/es unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3758528A (en) *	1970-03-13	1973-09-11	Science Union & Cie	Tricyclic compounds
US6599896B1 (en) *	1999-04-07	2003-07-29	Les Laboratoires Servier	Use of tianeptine in the production of medicaments to treat neurodegenerative pathologies

Also Published As

Publication number	Publication date
JO2844B1 (ar)	2014-09-15
TW201029981A (en)	2010-08-16
AR075295A1 (es)	2011-03-23
UY32216A (es)	2010-05-31

Legal Events

Date	Code	Title	Description
2024-04-21	MM4A	Annulment or lapse of patent due to non-payment of fees

Publication	Publication Date	Title
CN1163231C (zh)	2004-08-25	用于口服的美洛西肯的盖伦制剂
EP2870163B1 (en)	2018-09-19	Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof
ES2562843T3 (es)	2017-10-19	Forma IV de clorhidrato de ivabradina
RU2539590C2 (ru)	2015-01-20	Кристаллические формы саксаглиптина
TWI878810B (zh)	2025-04-01	製造及使用因多昔芬(endoxifen)之方法
CN1970547B (zh)	2011-04-06	非布司他的晶型及其制备方法
TW202235417A (zh)	2022-09-16	整合素抑制劑及其用途
CN107567444A (zh)	2018-01-09	用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物
US8124640B2 (en)	2012-02-28	Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof
BR112019012340A2 (pt)	2019-11-26	sais cristalinos e polimorfos de um antagonista p2x3
US8198268B2 (en)	2012-06-12	Tianeptine sulfate salt forms and methods of making and using the same
TWI903066B (zh)	2025-11-01	包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之口服用複合調配物
JP6093707B2 (ja)	2017-03-08	化合物製剤
JP2024539726A (ja)	2024-10-29	Ｎ－（（１ｒ，３ｓ）－３－（４－アセチルピペラジン－１－イル）シクロヘキシル）－４－フルオロ－７－メチル－１ｈ－インドール－２－カルボキサミドの結晶形態
TWI492937B (zh)	2015-07-21	噻萘普汀硫酸鹽型式及其製造及使用的方法
CN102453020A (zh)	2012-05-16	一种来那度胺的新晶型及其制备方法
CN103006648A (zh)	2013-04-03	一种马来酸左旋氨氯地平药物活性组合物及其制备方法
JP2026512051A (ja)	2026-04-14	ベンズイミダゾール誘導体の塩
TWI436988B (zh)	2014-05-11	７-〔（３-氯-６，１１-二氫-６-甲基二苯并〔ｃ，ｆ〕〔１，２〕噻氮呯-１１-基）胺〕庚酸ｓ，ｓ二氧化物之多晶型及其製造與使用方法
WO2017000270A1 (zh)	2017-01-05	枸橼酸舍曲林的2种晶型及其制备方法
CN102093309B (zh)	2012-07-04	非布司他的晶型及其制备方法
BR112020010135A2 (pt)	2021-03-23	formas polimórficas de maleato de trimebutina e método de usar as mesmas
CN119462561B (zh)	2025-04-25	化合物的晶型及其制备方法、原料药、组合物和用途
CN106692067B (zh)	2021-03-16	双嘧达莫固体分散体、口崩片及其制备方法
JP7506475B2 (ja)	2024-06-26	フェブキソスタット製剤